Unknown

Dataset Information

0

Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.


ABSTRACT: Patients with schizophrenia often suffer from cognitive deficits and negative symptoms that are poorly responsive to antipsychotics including clozapine. Clozapine-induced sedation can worsen cognition and impair social and occupational functioning.To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine.A double-blind, placebo-controlled, flexible-dosed 8-week pilot trial was conducted between September 2003 and September 2007, adding modafinil up to 300 mg/d to stabilized schizophrenia outpatients receiving clozapine. Psychopathology, cognition, and wakefulness/fatigue were assessed with standard rating scales.Thirty-five patients were randomly assigned to treatment with study drug and included in the analysis. Modafinil did not reduce negative symptoms or wakefulness/fatigue or improve cognition compared to placebo. Modafinil was well tolerated and did not worsen psychosis.Results of this pilot trial do not support routine use of modafinil to treat negative symptoms, cognitive deficits, or wakefulness/fatigue in patients on clozapine. However, given our limited power to detect a treatment effect and the clear possibility of a type II error, larger trials are needed to resolve or refute a potential therapeutic effect of uncertain magnitude.clinicaltrials.gov Identifier: NCT00573417.

SUBMITTER: Freudenreich O 

PROVIDER: S-EPMC5038350 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.

Freudenreich Oliver O   Henderson David C DC   Macklin Eric A EA   Evins A Eden AE   Fan Xiaoduo X   Cather Cori C   Walsh Jared P JP   Goff Donald C DC  

The Journal of clinical psychiatry 20090811 12


<h4>Background</h4>Patients with schizophrenia often suffer from cognitive deficits and negative symptoms that are poorly responsive to antipsychotics including clozapine. Clozapine-induced sedation can worsen cognition and impair social and occupational functioning.<h4>Objectives</h4>To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine.<h4>Method</h4>A double-bl  ...[more]

Similar Datasets

| S-EPMC5832639 | biostudies-literature
| S-EPMC4954262 | biostudies-literature
| S-EPMC2875545 | biostudies-literature
| S-EPMC5156367 | biostudies-literature
| S-EPMC2901366 | biostudies-literature
| S-EPMC3920313 | biostudies-literature
| S-EPMC6484692 | biostudies-literature
| S-EPMC3268840 | biostudies-literature
| S-EPMC4998932 | biostudies-other
| S-EPMC7241803 | biostudies-literature